Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'TYPE-1 PROTEASE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 173 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Matsumoto, H; Kimura, T; Hamawaki, T; Kumagai, A; Goto, T; Sano, K; Hayashi, Y; Kiso, Y
      Design, synthesis, and biological evaluation of anti-HIV double-drugs: Conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor through spontaneously cleavable linkers

      BIOORGANIC & MEDICINAL CHEMISTRY
    2. Le, VD; Mak, CC; Lin, YC; Elder, JH; Wong, CH
      Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine

      BIOORGANIC & MEDICINAL CHEMISTRY
    3. Wang, L; Duan, Y; Stouten, P; De Lucca, GV; Klabe, RM; Kollman, PA
      Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations

      JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
    4. Dronda, F; Casado, JL; Moreno, S; Hertogs, K; Garcia-Arata, I; Antela, A; Perez-Elias, MJ; Ruiz, L; Larder, B
      Phenotypic cross-resistance to nelfinavir: The role of prior antiretroviral therapy and the number of mutations in the protease gene

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    5. Quiros-Roldan, E; Signorini, S; Castelli, F; Torti, C; Patroni, A; Airoldi, M; Carosi, G
      Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy

      JOURNAL OF CLINICAL LABORATORY ANALYSIS
    6. Goto, T; Nakano, T; Kohno, T; Morimatsu, S; Morita, C; Hong, W; Kiso, Y; Nakai, M; Sano, K
      Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells

      JOURNAL OF MEDICAL VIROLOGY
    7. Huff, JR; Kahn, J
      Discovery and clinical development of HIV-1 protease inhibitors

      ADVANCES IN PROTEIN CHEMISTRY, VOL 56
    8. Merkulov, GV; Lawler, JF; Eby, Y; Boeke, JD
      Ty1 proteolytic cleavage sites are required for transposition: All sites are not created equal

      JOURNAL OF VIROLOGY
    9. Sheaffer, AK; Newcomb, WW; Gao, M; Yu, D; Weller, SK; Brown, JC; Tenney, DJ
      Herpes simplex virus DNA cleavage and packaging proteins associate with the procapsid prior to its maturation

      JOURNAL OF VIROLOGY
    10. Schatz, GW; Reinking, J; Zippin, J; Nicholson, LK; Vogt, VM
      Importance of the N terminus of rous sarcoma virus protease for structure and enzymatic function

      JOURNAL OF VIROLOGY
    11. Buisson, M; Valette, E; Hernandez, JF; Baudin, F; Ebel, C; Morand, P; Seigneurin, JM; Arlaud, GJ; Ruigrok, RWH
      Functional determinants of the Epstein-Barr virus protease

      JOURNAL OF MOLECULAR BIOLOGY
    12. Dash, C; Rao, M
      Interactions of a novel inhibitor from an extremophilic Bacillus sp with HIV-1 protease - Implications for the mechanism of inactivation

      JOURNAL OF BIOLOGICAL CHEMISTRY
    13. Ma, C; Nakamura, N; Hattori, M
      Inhibitory effects on HIV-1 protease of tri-p-coumaroylspermidine from Artemisia caruifolia and related amides

      CHEMICAL & PHARMACEUTICAL BULLETIN
    14. Huang, XY; Knoell, CT; Frey, G; Hazegh-Azam, M; Tashijian, AH; Hedstrom, L; Abeles, RH; Timasheff, SN
      Modulation of recombinant human prostate-specific antigen: Activation by Hofmeister salts and inhibition by azapeptides

      BIOCHEMISTRY
    15. Satomi, S; Yamasaki, Y; Tsuzuki, S; Hitomi, Y; Iwanaga, T; Fushiki, T
      A role for membrane-type serine protease (MT-SP1) in intestinal epithelialturnover

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    16. Piana, S; Sebastiani, D; Carloni, P; Parrinello, M
      Ab initio molecular dynamics-based assignment of the protonation state of pepstatin A/HIV-1 protease cleavage site

      JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
    17. Fessel, WJ; Follansbee, SE; Young, TP
      Salvage therapy and formulation of highly active antiretroviral therapy

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    18. Walter, H; Schmidt, B; Rascu, A; Helm, M; Moschik, B; Paatz, C; Kurowski, M; Korn, K; Uberla, K; Harrer, T
      Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy

      ANTIVIRAL THERAPY
    19. Winters, MA; Baxter, JD; Mayers, DL; Wentworth, DN; Hoover, ML; Neaton, JD; Merigan, TC
      Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens

      ANTIVIRAL THERAPY
    20. Park, SH; Raines, RT
      Genetic selection for dissociative inhibitors of designated protein-protein interactions

      NATURE BIOTECHNOLOGY
    21. Scott, WRP; Schiffer, CA
      Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance

      STRUCTURE
    22. Hong, L; Zhang, XJC; Hartsuck, JA; Tang, J
      Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance

      PROTEIN SCIENCE
    23. Rusconi, S; Moroni, M
      Clinical impact of anti retroviral resistance testing: current problems and future directions

      INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
    24. Caflisch, A; Schramm, HJ; Karplus, M
      Design of dimerization inhibitors of HIV-1 aspartic proteinase: A computer-based combinatorial approach

      JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
    25. Li, LY; Stewart, BH; Fleisher, D
      Oral delivery of HIV-protease inhibitors

      CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
    26. Moatti, JP; Spire, B; Duran, S
      A review of socio-behavioural studies on adherence to antiretroviral treatments: beyond biomedical models?

      REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE
    27. Ehnlund, M; Bjorling, E
      Fine characterization of the antigenic site within the flap region in the protease protein of HIV-1

      ARCHIVES OF VIROLOGY
    28. Perez-Elias, MJ; Lanier, R; Munoz, V; Garcia-Arata, I; Casado, JL; Marti-Belda, P; Moreno, A; Dronda, F; Antela, A; Marco, S; Moreno, S
      Phenotypic testing predicts virological response in successive protease inhibitor-based regimens

      AIDS
    29. Wlodawer, A; Gustchina, A
      Structural and biochemical studies of retroviral proteases

      BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY
    30. Gulnik, S; Erickson, JW; Xie, D
      HIV protease: Enzyme function and drug resistance

      VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 58
    31. Robinson, BS; Riccardi, KA; Gong, YF; Guo, Q; Stock, DA; Blair, WS; Terry, BJ; Deminie, CA; Djang, F; Colonno, RJ; Lin, PF
      BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    32. Schmidt, B; Korn, K; Moschik, B; Paatz, C; Uberla, K; Walter, H
      Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    33. Dawson, PE; Kent, SBH
      Synthesis of native proteins by chemical ligation

      ANNUAL REVIEW OF BIOCHEMISTRY
    34. Baca, M; Kent, SBH
      Protein backbone engineering through total chemical synthesis: New insightinto the mechanism of HIV-1 protease catalysis

      TETRAHEDRON
    35. Wang, W; Kollman, PA
      Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model

      JOURNAL OF MOLECULAR BIOLOGY
    36. Prabu-Jeyabalan, M; Nalivaika, E; Schiffer, CA
      How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease

      JOURNAL OF MOLECULAR BIOLOGY
    37. Beaulieu, PL; Anderson, PC; Cameron, DR; Croteau, G; Gorys, V; Grand-Maitre, C; Lamarre, D; Liard, F; Paris, W; Plamondon, L; Soucy, F; Thibeault, D; Wernic, D; Yoakim, C; Pav, S; Tong, L
      2 ',6 '-dimethylphenoxyacetyl: A new achiral high affinity P-3-P-2 ligand for peptidomimetic-based HIV protease inhibitors

      JOURNAL OF MEDICINAL CHEMISTRY
    38. Figueiredo, LJO; Antunes, OAC
      Chemometric classification of HIV-1 protease inhibitors

      INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY
    39. Figgitt, DP; Plosker, GL
      Saquinavir soft-gel capsule - An updated review of its use in the management of HIV infection

      DRUGS
    40. Panchal, SC; Pillai, B; Hosur, MV; Hosur, RV
      HIV-1 protease tethered heterodimer-pepstatin-A complex: NMR characterization

      CURRENT SCIENCE
    41. Pivazyan, AD; Matteson, DS; Fabry-Asztalos, L; Singh, RP; Lin, P; Blair, W; Guo, K; Robinson, B; Prusoff, WH
      Inhibition of HIV-1 protease by a boron-modified polypeptide

      BIOCHEMICAL PHARMACOLOGY
    42. Snasel, J; Shoeman, R; Horejsi, M; Hruskova-Heidingsfeldova, O; Sedlacek, J; Ruml, T; Pichova, I
      Cleavage of vimentin by different retroviral proteases

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    43. Keinan, S; Avnir, D
      Quantitative symmetry in structure-activity correlations: The near C-2 symmetry of inhibitor/HIV protease complexes

      JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
    44. Pai, VB; Nahata, MC
      Nelfinavir mesylate: A protease inhibitor

      ANNALS OF PHARMACOTHERAPY
    45. Moret, EE; van Wijk, MC; Kostense, AS; Gillies, MB
      Scoring peptide(mimetic)-protein interactions

      MEDICINAL CHEMISTRY RESEARCH
    46. Hawkins, V; Shen, Q; Chiueh, CC
      Kynostatin and 17 beta-estradiol prevent the apoptotic death of human neuroblastoma cells exposed to HIV-1 protease

      JOURNAL OF BIOMEDICAL SCIENCE
    47. Ishima, R; Freedberg, DI; Wang, YX; Louis, JM; Torchia, DA
      Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function

      STRUCTURE WITH FOLDING & DESIGN
    48. Anilkumar, AT; Goto, K; Takahashi, T; Ishizaki, K; Kaga, H
      Lipase-mediated resolution of cis-1-amino-2-indanol, the key component of the HIV protease inhibitor indinavir

      TETRAHEDRON-ASYMMETRY
    49. Bonfanti, P; Capetti, A; Rizzardini, G
      HIV disease treatment in the era of HAART

      BIOMEDICINE & PHARMACOTHERAPY
    50. Palmer, S; Shafer, RW; Merigan, TC
      Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development

      AIDS
    51. Nijhuis, M; Schuurman, R; de Jong, D; Erickson, J; Gustchina, E; Albert, J; Schipper, P; Gulnik, S; Boucher, CAB
      Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

      AIDS
    52. Erickson, JW; Gulnik, SV; Markowitz, M
      Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies

      AIDS
    53. Katsuraya, K; Jeon, KJ; Nakashima, H; Uryu, T
      NMR studies on structure and action mechanism of sulfated dodecyl laminaripentaoside with high anti-human immunodeficiency virus activity

      POLYMER JOURNAL
    54. Wilk, T; Gowen, B; Fuller, SD
      Actin associates with the nucleocapsid domain of the human immunodeficiency virus Gag polyprotein

      JOURNAL OF VIROLOGY
    55. Dasgupta, A; Wilson, DW
      ATP depletion blocks herpes simplex virus DNA packaging acid capsid maturation

      JOURNAL OF VIROLOGY
    56. Olsen, DB; Stahlhut, MW; Rutkowski, CA; Schock, HB; vanOlden, AL; Kuo, LC
      Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors

      JOURNAL OF BIOLOGICAL CHEMISTRY
    57. Mahalingam, B; Louis, JM; Reed, CC; Adomat, JM; Krouse, J; Wang, YF; Harrison, RW; Weber, IT
      Structural and kinetic analysis of drug resistant mutants of HIV-1 protease

      EUROPEAN JOURNAL OF BIOCHEMISTRY
    58. Holwerda, B
      Activity in monomers of human cytomegalovirus protease

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    59. Bonneau, PR; Hasani, F; Plouffe, C; Malenfant, E; LaPlante, SR; Guse, I; Ogilvie, WW; Plante, R; Davidson, WC; Hopkins, JL; Morelock, MM; Cordingley, MG; Deziel, R
      Inhibition of human cytomegalovirus protease by monocyclic beta-lactam derivatives: Kinetic characterization using a fluorescent probe

      JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
    60. KAKUDA TN; STRUBLE KA; PISCITELLI SC
      PROTEASE INHIBITORS FOR THE TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUSINFECTION

      American journal of health-system pharmacy
    61. RODGERS JD; LAM PYS; JOHNSON BL; WANG HS; KO SS; SEITZ SP; TRAINOR GL; ANDERSON PS; KLABE RM; BACHELER LT; CORDOVA B; GARBER S; REID C; WRIGHT MR; CHANG CH; ERICKSONVIITANEN S
      DESIGN AND SELECTION OF DMP-850 AND DMP-851 - THE NEXT-GENERATION OF CYCLIC UREA HIV PROTEASE INHIBITORS

      Chemistry & biology
    62. WLODAWER A; VONDRASEK J
      INHIBITORS OF HIV-1 PROTEASE - A MAJOR SUCCESS OF STRUCTURE-ASSISTED DRUG DESIGN

      Annual review of biophysics and biomolecular structure
    63. Chen, XQ; Kempf, DJ; Sham, HL; Green, BE; Molla, A; Korneyeva, M; Vasavanonda, S; Wideburg, NE; Saldivar, A; Marsh, KC; McDonald, E; Norbeck, DW
      Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P-3 ligands

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    64. ALEU J; FRONZA G; FUGANTI C; PEROZZO V; SERRA S
      ON THE BAKERS-YEAST MEDIATED TRANSFORMATION OF ALPHA-BROMOENONES - SYNTHESIS OF (1S,2R)-2-BROMOINDAN-1-OL AND (2S,3S)-3-BROMO-4-PHENYLBUTAN-2-OL

      Tetrahedron : asymmetry
    65. HOLLOWAY MK
      A-PRIORI PREDICTION OF LIGAND AFFINITY BY ENERGY MINIMIZATION

      Perspectives in drug discovery and design
    66. SAEZLLORENS X; RAMILO O
      EARLY EXPERIENCE WITH PROTEASE INHIBITORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN

      The Pediatric infectious disease journal
    67. SCHAFFER L; VERKHIVKER GM
      PREDICTING STRUCTURAL EFFECTS IN HIV-1 PROTEASE MUTANT COMPLEXES WITHFLEXIBLE LIGAND DOCKING AND PROTEIN SIDE-CHAIN OPTIMIZATION

      Proteins
    68. SUDOH M; PAULETTI GM; YAO WQ; MOSER W; YOKOYAMA A; PASTERNAK A; SPRENGELER PA; SMITH AB; HIRSCHMANN R; BORCHARDT RT
      TRANSPORT CHARACTERISTICS OF PEPTIDOMIMETICS - EFFECT OF THE PYRROLINONE BIOISOSTERE ON TRANSPORT ACROSS CACO-2 CELL MONOLAYERS

      Pharmaceutical research
    69. WEBER IT; CAVANAUGH DS; HARRISON RW
      MODELS OF HIV-1 PROTEASE WITH PEPTIDES REPRESENTING ITS NATURAL SUBSTRATES

      Journal of molecular structure. Theochem
    70. BEACH JW
      CHEMOTHERAPEUTIC-AGENTS FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - MECHANISM OF ACTION, PHARMACOKINETICS, METABOLISM AND ADVERSE REACTIONS

      Clinical therapeutics
    71. Sham, HL; Kempf, DJ; Molla, A; Marsh, KC; Kumar, GN; Chen, CM; Kati, W; Stewart, K; Lal, R; Hsu, A; Betebenner, D; Korneyeva, M; Vasavanonda, S; McDonald, E; Saldivar, A; Wideburg, N; Chen, XQ; Niu, P; Park, C; Jayanti, V; Grabowski, B; Granneman, GR; Sun, E; Japour, AJ; Leonard, JM; Plattner, JJ; Norbeck, DW
      ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    72. Melnick, L; Yang, SS; Rossi, R; Zepp, C; Heefner, D
      An Escherichia coli expression assay and screen for human immunodeficiencyvirus protease variants with decreased susceptibility to indinavir

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    73. FLEXNER C
      HIV-PROTEASE INHIBITORS

      The New England journal of medicine
    74. JADHAV PK; WOERNER FJ; LAM PYS; HODGE CN; EYERMANN CJ; MAN HW; DANEKER WF; BACHELER LT; RAYNER MM; MEEK JL; ERICKSONVIITANEN S; JACKSON DA; CALABRESE JC; SCHADT M; CHANG CH
      NONPEPTIDE CYCLIC CYANOGUANIDINES AS HIV-1 PROTEASE INHIBITORS - SYNTHESIS, STRUCTURE-ACTIVITY-RELATIONSHIPS, AND X-RAY CRYSTAL-STRUCTURE STUDIES

      Journal of medicinal chemistry
    75. KEMPF DJ; SHAM HL; MARSH KC; FLENTGE CA; BETEBENNER D; GREEN BE; MCDONALD E; VASAVANONDA S; SALDIVAR A; WIDEBURG NE; KATI WM; RUIZ L; ZHAO C; FINO LM; PATTERSON J; MOLLA A; PLATTNER JJ; NORBECK DW
      DISCOVERY OF RITONAVIR, A POTENT INHIBITOR OF HIV PROTEASE WITH HIGH ORAL BIOAVAILABILITY AND CLINICAL EFFICACY

      Journal of medicinal chemistry
    76. PERNO CF; NEWCOMB FM; DAVIS DA; AQUARO S; HUMPHREY RW; CALIO R; YARCHOAN R
      RELATIVE POTENCY OF PROTEASE INHIBITORS IN MONOCYTES MACROPHAGES ACUTELY AND CHRONICALLY INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS/

      The Journal of infectious diseases
    77. ALA PJ; DELOSKEY RJ; HUSTON EE; JADHAV PK; LAM PYS; EYERMANN CJ; HODGE CN; SCHADT MC; LEWANDOWSKI FA; WEBER PC; MCCABE DD; DUKE JL; CHANG CH
      MOLECULAR RECOGNITION OF CYCLIC UREA HIV-1 PROTEASE INHIBITORS

      The Journal of biological chemistry
    78. SWAIRJO MA; TOWLER EM; DEBOUCK C; ABDELMEGUID SS
      STRUCTURAL ROLE OF THE 30S LOOP IN DETERMINING THE LIGAND SPECIFICITYOF THE HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE

      Biochemistry
    79. KLABE RM; BACHELER LT; ALA PJ; ERICKSONVIITANEN S; MEEK JL
      RESISTANCE TO HIV PROTEASE INHIBITORS - A COMPARISON OF ENZYME-INHIBITION AND ANTIVIRAL POTENCY

      Biochemistry
    80. NAIR AC; MIERTUS S; TOSSI A; ROMEO D
      A COMPUTATIONAL STUDY OF THE RESISTANCE OF HIV-1 ASPARTIC PROTEASE TOTHE INHIBITORS ABT-538 AND VX-478 AND DESIGN OF NEW ANALOGS

      Biochemical and biophysical research communications
    81. TAWA GJ; TOPOL IA; BURT SK; ERICKSON JW
      CALCULATION OF RELATIVE BINDING FREE-ENERGIES OF PEPTIDIC INHIBITORS TO HIV-1 PROTEASE AND ITS I84V MUTANT

      Journal of the American Chemical Society
    82. HODGE CN; LAM PYS; EYERMANN CJ; JADHAV PK; RU Y; FERNANDEZ CH; DELUCCA GV; CHANG CH; KALTENBACH RF; HOLLER ER; WOERNER F; DANEKER WF; EMMETT G; CALABRESE JC; ALDRICH PE
      CALCULATED AND EXPERIMENTAL LOW-ENERGY CONFORMATIONS OF CYCLIC UREA HIV PROTEASE INHIBITORS

      Journal of the American Chemical Society
    83. KISSELEV AF; MENTELE R; VONDERHELM K
      CLEAVAGE OF THE COMPLEMENT-SYSTEM C3 COMPONENT BY HIV-1 PROTEINASE

      Biological chemistry
    84. HOMA FL; BROWN JC
      CAPSID ASSEMBLY AND DNA PACKAGING IN HERPES-SIMPLEX VIRUS

      Reviews in medical virology
    85. MILLER M; GELLER M; GRIBSKOV M; KENT SBH
      ANALYSIS OF THE STRUCTURE OF CHEMICALLY SYNTHESIZED HIV-1 PROTEASE COMPLEXED WITH A HEXAPEPTIDE INHIBITOR .1. CRYSTALLOGRAPHIC REFINEMENT OF 2 ANGSTROM DATA

      Proteins
    86. MCKERCHER G; BONNEAU PR; LAGACE L; THIBEAULT D; MASSARIOL MJ; KROGSRUD R; LAWETZ C; MCDONALD PC; CORDINGLEY MG
      IMPROVED PURIFICATION PROTOCOL OF THE HSV-1 PROTEASE CATALYTIC DOMAIN, USING IMMUNOAFFINITY

      Biochemistry and cell biology
    87. LIN JH
      HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE INHIBITORS - FROM DRUG DESIGN TO CLINICAL-STUDIES

      Advanced drug delivery reviews
    88. KEMPF DJ; MARSH KC; KUMAR G; RODRIGUES AD; DENISSEN JF; MCDONALD E; KUKULKA MJ; HSU A; GRANNEMAN GR; BAROLDI PA; SUN E; PIZZUTI D; PLATTNER JJ; NORBECK DW; LEONARD JM
      PHARMACOKINETIC ENHANCEMENT OF INHIBITORS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE BY COADMINISTRATION WITH RITONAVIR

      Antimicrobial agents and chemotherapy
    89. GULICK RM; MELLORS JW; HAVLIR D; ERON JJ; GONZALEZ C; MCMAHON D; RICHMAN DD; VALENTINE FT; JONAS L; MEIBOHM A; EMINI EA; CHODAKEWITZ JA
      TREATMENT WITH INDINAVIR, ZIDOVUDINE, AND LAMIVUDINE IN ADULTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND PRIOR ANTIRETROVIRAL THERAPY

      The New England journal of medicine
    90. QIU XY; JANSON CA; CULP JS; RICHARDSON B; DEBOUCK C; SMITH WW; ABDELMEGUID SS
      CRYSTAL-STRUCTURE OF VARICELLA-ZOSTER VIRUS PROTEASE

      Proceedings of the National Academy of Sciences of the United Statesof America
    91. CHURCH GA; WILSON DW
      STUDY OF HERPES-SIMPLEX VIRUS MATURATION DURING A SYNCHRONOUS WAVE OFASSEMBLY

      Journal of virology
    92. HIPPENMEYER PJ; RANKIN AM; LUCKOW VA; NEISES GR
      PROTEASE-DEFICIENT HERPES-SIMPLEX VIRUS PROTECTS MICE FROM LETHAL HERPESVIRUS-INFECTION

      Journal of virology
    93. GIRON ML; COLAS S; WYBIER J; ROZAIN F; EMANOILRAVIER R
      EXPRESSION AND MATURATION OF HUMAN FOAMY VIRUS GAG PRECURSOR POLYPEPTIDES

      Journal of virology
    94. HULTEN J; BONHAM NM; NILLROTH U; HANSSON T; ZUCCARELLO G; BOUZIDE A; AQVIST J; CLASSON B; DANIELSON UH; KARLEN A; KVARNSTROM I; SAMUELSSON B; HALLBERG A
      CYCLIC HIV-1 PROTEASE INHIBITORS DERIVED FROM MANNITOL - SYNTHESIS, INHIBITORY POTENCIES, AND COMPUTATIONAL PREDICTIONS OF BINDING AFFINITIES

      Journal of medicinal chemistry
    95. BACKBRO K; LOWGREN S; OSTERLUND K; ATEPO J; UNGE T; HULTEN J; BONHAM NM; SCHAAL W; KARLEN A; HALLBERG A
      UNEXPECTED BINDING MODE OF A CYCLIC SULFAMIDE HIV-1 PROTEASE INHIBITOR

      Journal of medicinal chemistry
    96. APELER H; GOTTSCHALK U; GUNTERMANN D; HANSEN J; MASSEN J; SCHMIDT E; SCHNEIDER KH; SCHNEIDEREIT M; RUBSAMENWAIGMANN H
      EXPRESSION OF NATURAL AND SYNTHETIC GENES ENCODING HERPES-SIMPLEX VIRUS-1 PROTEASE IN ESCHERICHIA-COLI AND PURIFICATION OF THE PROTEIN

      European journal of biochemistry
    97. VANCE JE; LEBLANC DA; LONDON RE
      CLEAVAGE OF THE X-PRO PEPTIDE-BOND BY PEPSIN IS SPECIFIC FOR THE TRANS ISOMER

      Biochemistry
    98. LACO GS; SCHALKHIHI C; LUBKOWSKI J; MORRIS G; ZDANOV A; OLSON A; ELDER JH; WLODAWER A; GUSTCHINA A
      CRYSTAL-STRUCTURES OF THE INACTIVE D30N MUTANT OF FELINE IMMUNODEFICIENCY VIRUS PROTEASE COMPLEXED WITH A SUBSTRATE AND AN INHIBITOR

      Biochemistry
    99. TOWLER EM; THOMPSON SK; TOMASZEK T; DEBOUCK C
      IDENTIFICATION OF A LOOP OUTSIDE THE ACTIVE-SITE CAVITY OF THE HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASES WHICH CONFERS INHIBITOR SPECIFICITY

      Biochemistry
    100. KOMAI T; YAGI R; SUZUKISUNAGAWA H; ISHIKAWA Y; KASUYA A; MIYAMOTO S; HANDA H; NISHIGAKI T
      INHIBITION OF HIV-1 PROTEASE BY OXIM DERIVATIVES

      Biochemical and biophysical research communications


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/05/20 alle ore 02:04:37